



Cite this: *Biomater. Sci.*, 2024, **12**, 4275

## Molecular basis for non-invasive diagnostics of cardiac amyloids using bone tracers

Emily Lewkowicz, Shobini Jayaraman and Olga Gursky \*

Amyloid diseases including Alzheimer's, Parkinson's and over 30 others are incurable life-threatening disorders caused by abnormal protein deposition as fibrils in various organs. Cardiac amyloidosis is particularly challenging to diagnose and treat. Identification of the fibril-forming protein, which in the heart is usually amyloid transthyretin (ATTR) or amyloid immunoglobulin light chain (AL), is paramount to treatment. A transformative non-invasive diagnostic modality is imaging using technetium-labeled pyrophosphate or diphosphonate bone tracers,  $^{99m}\text{Tc}$ -PYP/DPD/HMDP. For unknown reasons, these tracers show preferential uptake by ATTR deposits. The tracer-binding moiety is unknown and potentially involves amyloid fibrils and/or amyloid-associated calcific deposits. We propose that, like in the bone, the tracers chelate to surface-bound  $\text{Ca}^{2+}$  in amyloid. In high-affinity protein sites,  $\text{Ca}^{2+}$  is coordinated by pairs of acidic residues. To identify such residues on amyloids, we harnessed atomic structures of patient-derived cardiac amyloids determined using cryogenic electron microscopy since 2019. These structures help explain why most but not all ATTR deposits uptake  $^{99m}\text{Tc}$ -PYP/DPD/HMDP radiotracers, while in AL the opposite is true. Moreover, fibril structures help explain greater microcalcification observed in ATTR vs. AL deposits. These findings may aid the diagnostics and therapeutic targeting of cardiac amyloidosis and are relevant to other amyloids.

Received 17th June 2024,  
Accepted 19th July 2024

DOI: 10.1039/d4bm00816b

rs.c.li/biomaterials-science

### 1. Introduction

Amyloidoses are underdiagnosed life-threatening diseases wherein normally soluble proteins or peptides deposit as insoluble fibrils in vital organs. Amyloid fibril formation involves self-assembly of many protein copies into an insoluble polymer. Over 40 fibril-forming proteins have been identified to-date that deposit as pathologic amyloids in humans.<sup>1,2</sup> Some fibril-forming proteins such as Tau deposit in more than one amyloid disease.<sup>3</sup> Amyloid deposition can damage cells and organs, ultimately leading to organ failure. In neurodegenerative disorders such as Alzheimer's, Parkinson's or prion diseases, amyloid fibrils deposit in the brain. In other systemic or localized amyloidoses, the afflicted organs often involve the kidneys, liver and heart.<sup>1</sup> Amyloid deposition in the heart is lethal if untreated, and treatment of cardiac amyloidosis is particularly challenging.<sup>1,4,5</sup> Although amyloid diseases are currently incurable, disease-modifying therapies have emerged that prolong patient life and improve its quality.<sup>6</sup> The therapeutic outcomes depend critically on the accurate and timely diagnostics, which is a major challenge.<sup>1,4,5</sup> This mini-review

is focused on the preferred diagnostic method for cardiac amyloidosis and its molecular underpinnings.

### 2. Recent advances in the diagnostics and treatment of cardiac amyloidosis

Cardiac amyloidosis is a group of diseases that often present as cardiomyopathy. Once considered a rare fatal disease, cardiac amyloidosis afflicts a significant fraction of patients with heart failure (up to 20% by some estimates), particularly aging men.<sup>4-6</sup> Although the numbers keep rising as the population ages and the diagnostic methods improve, the disease can be actively managed thanks to major pharmacological advances.<sup>4-6</sup> Cardiac amyloidosis results from the extracellular deposition of a plasma protein, which is typically amyloid transthyretin (ATTR), amyloid immunoglobulin light chains (AL) or, occasionally, amyloid apolipoprotein A-I (ApoAI).<sup>4</sup> Co-deposition of different fibril-forming proteins perhaps due to heterogeneous cross-seeding is an emerging challenge in the field.<sup>8,9</sup> Current pharmacotherapies for ATTR include small-molecule stabilizers of the native protein conformation (e.g. tafamidis); oligonucleotide-based gene-silencing approaches;

Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. E-mail: gursky@bu.edu



newly developed CRISPR-Cas9-based gene editing tools; and antibody-mediated amyloid removal.<sup>6</sup> Current pharmacotherapies for AL include chemotherapy targeting the aberrant plasma cell clone to block the generation of the amyloidogenic light chain, along with supportive therapies; new therapies are being developed, such as antibody-mediated fibril removal.<sup>7</sup> In a subset of patients, organ transplantation (liver for ATTR or AApoAI, bone marrow for AL) can be used to block the aberrant protein secretion.<sup>4</sup> These protein-targeting approaches necessitate timely and accurate identification of the fibril-forming protein, or amyloid typing, which is paramount for treatment.

The gold standard for amyloid typing has been organ biopsy followed by immunohistochemical or mass spectrometry analysis to identify the fibrillar protein and associated “amyloid signature” proteins. The biopsy results are more accurate for the target *vs.* surrogate organ, *e.g.* heart *vs.* fat. However, endomyocardial biopsy is a risky procedure not suited for many patients. Since 2016, the field has been transformed by the application of noninvasive methods for diagnosis and differentiation of cardiac ATTR *vs.* AL, which became the preferred modality in many countries.<sup>5,10,11</sup> The methods involve scintigraphy using technetium-labeled bone tracers pyrophosphate (<sup>99m</sup>Tc-PYP), hydroxymethylene diphosphonate (<sup>99m</sup>Tc-HMDP) or 3,3-diphosphono-1,2-propanodicarboxylate (<sup>99m</sup>Tc-DPD), followed by 3D nuclear imaging to differentiate tracer binding to amyloid deposits *vs.* Ca<sup>2+</sup> in blood (Fig. 1A and B).<sup>5</sup> This diagnostic modality is currently used for ~70% of patients with cardiac amyloidosis, yet gray areas remain. Amyloid diagnostics using <sup>99m</sup>Tc scintigraphy is prone to false negatives, false positives require additional testing, the method does not assess the overall amyloid load and is not suited as a readout for treatment, and the tracer binding moiety is unknown.<sup>5,10,12</sup> Some of these issues and their potential molecular underpinnings are addressed below.

### 3. Key challenges and unanswered questions in amyloid typing

For unknown reasons, the <sup>99m</sup>Tc-PYP/DPD/HMDP radiotracers preferentially (although not only and not always) colocalize with ATTR *vs.* AL or AApoAI deposits.<sup>5,10</sup> This differential uptake enables one to distinguish between ATTR and other types of cardiac amyloidosis. Although misinterpretation of the images remains the major source of false positives and false negatives, there are other sources of error. In fact, some AL patients show substantial radiotracer uptake, leading to false positives in ATTR diagnostics. Still, if the uptake is high (grade 2 or 3 on the Perugini scale, Fig. 1B) and AL amyloidosis has been excluded by other methods, ATTR can be diagnosed with high certainty. Furthermore, false negatives in <sup>99m</sup>Tc scintigraphy have also been reported, and are thought to stem from the low amyloid load at early disease stages, differences in TTR expression, and/or tracer uptake by most but not

all ATTR deposits.<sup>5,10</sup> Notably, the reasons for the fiber-specific tracer uptake are unknown.

Furthermore, although the <sup>99m</sup>Tc scintigraphy provides a useful diagnostic tool, recent reports show that it is not a good readout for the changes in cardiac function in response to treatment. ATTR patients treated with tafamidis (a small-molecule stabilizer of the native transthyretin tetramer) or with an RNAi-based gene silencing therapy show decreased radiotracer uptake, yet their cardiac function does not improve.<sup>12</sup> We and others hypothesize that the tracer is taken up only by the surfaces of newly formed amyloids, while in mature amyloids tracer binding sites are blocked by other molecules deposited on amyloid surface. In fact, amyloid deposits usually localize in the areas of excessive collagen deposition, or fibrosis, suggesting amyloid sequestration by the extracellular matrix molecules such as collagen fibrils. Intimate amyloid-collagen interactions have been implicated in the collagen-induced inhibition of amyloid phagocytosis and clearance *in vivo* and *in vitro*.<sup>13</sup> Moreover, amyloid-collagen superstructures have been observed in patient-derived AL fibrils using a combination of cryo-EM and cryo-electron tomography.<sup>14</sup> We posit that intimate interactions of amyloids with collagens and perhaps other extracellular matrix components interfere with the tracer uptake and influence the biological properties of amyloids and associated calcification. Such interactions extend to other protein amyloids<sup>15</sup> and are actively explored by us and others.

Perhaps the major gap in our understanding of <sup>99m</sup>Tc scintigraphy of amyloids is that the radiotracer-binding moiety is unknown. This moiety potentially involves amyloid fibrils and/or calcific deposits associated with cardiac amyloidosis.<sup>16</sup> Calcification in collagen-rich regions, which for unknown reasons is greater in cardiac ATTR *vs.* AL patients,<sup>16,17</sup> is probably not the only mechanism explaining preferential tracer uptake by ATTR deposits.<sup>5,17</sup> Identifying the radiotracer-binding moiety is necessary to elucidate the molecular basis of <sup>99m</sup>Tc scintigraphy, understand its limitations, and potentially identify new therapeutic targets.

### 4. Calcium binding and fibril-specific radiotracer uptake by ATTR amyloids

In bone and calcific deposits, PYP and diphosphonate radiotracers chelate to Ca<sup>2+</sup> ions.<sup>18</sup> Our central premise is that, in addition to calcific deposits, protein amyloids uptake PYP/DPD/HMPD radiotracers *via* arrays of surface-bound Ca<sup>2+</sup> ions. Metal ion binding to amyloid has been predicted<sup>3,19</sup> and observed experimentally<sup>20</sup> (Fig. 2A). Moreover, several lines of experimental evidence suggest that phosphates in <sup>99m</sup>Tc-PYP/DPD/HMPD radiotracers can bind Ca<sup>2+</sup> in amyloid.<sup>21</sup> Current evidence includes: *in vitro* binding of <sup>99m</sup>Tc-DPD to synthetic amyloid fibrils;<sup>22</sup> destabilization and aggregation of native transthyretin upon calcium binding *in vitro*;<sup>23</sup> animal model studies showing that the anti-ATTR antibody enhances rapid disappearance of the amyloid-associated <sup>99m</sup>Tc-PYP signal in





**Fig. 1** Technetium-labeled bone tracers used for diagnostic imaging of cardiac amyloid. (A) <sup>99m</sup>Tc-labeled radiotracer molecules. <sup>99m</sup>Tc-PYP is preferentially used in the USA, while <sup>99m</sup>Tc-DPD and <sup>99m</sup>Tc-HMDP are widely used in Europe.<sup>5</sup> (B) Radiographs using <sup>99m</sup>Tc-PYP scintigraphy and single-photon emission computed tomography (SPECT) to visualize and quantify the tracer uptake in the heart. Numbers indicate the degree of uptake, from grade 0 (no uptake) to grade 3 (high uptake); grades 2 and 3 are often observed in untreated ATTR patients. Reproduced from Dorbala *et al.*<sup>11</sup> with permission from Elsevier, copyright 2020.


an ATTR rat model;<sup>21</sup> deposition of calcium phosphate immediately adjacent to cardiac amyloid fibrils of ATTR (but not AL) observed in some clinical human studies.<sup>17,24</sup> Taken together, these findings suggest radiotracer binding to amyloid surface. Below we propose structural underpinnings for such binding and its fibril specificity.

ATTR features two fibril types: the predominant type-A fibrils contain both full-length and fragmented TTR, while type-B fibrils contain only full-length TTR. Wild-type TTR (in ATTRwt) and most ATTR variants (in ATTRv, which typically feature single-point substitutions) form type-A fibrils; few ATTRv (Phe64Leu and Tyr114Cys) feature type-B fibrils; Val30Met forms either type-A or type-B fibrils in different patients. For unknown reasons, only type-A fibrils uptake radiotracers.<sup>5</sup> Amyloid fibril structures suggest an explanation.

## 5. Amyloid fibril structures suggest surface arrays of Ca<sup>2+</sup> binding sites

Calcium binding sites in proteins are highly variable in metal ion coordination, which can involve 4–8 oxygens from acidic and polar groups including water molecules, and range in affinity from millimolar to nanomolar.<sup>25</sup> High-affinity Ca<sup>2+</sup> binding sites involve two acidic residues that balance the charge; in contiguous sites, these residues are close in the primary structure, which minimizes the entropic penalty of binding and increases the affinity. Notably, some but not all amyloids feature exposed contiguous pairs of acidic residues (Fig. 2 and 3). Such residues form periodic arrays along the fibril surface (Fig. 2), which is unique





**Fig. 2** Amyloids display periodic ligand binding sites on the fibril surface, including acidic residue pairs that can bind calcium. (A) Cryo-EM structures of patient-derived  $A\beta_{1-42}$  type-I and type-II fibers show periodic arrays of metal ions bound by acidic residue pairs, Glu22-Asp23;<sup>20</sup> type-II fibril structure is shown. (B) Cryo-EM structures of ATTR type-A fibrils feature surface arrays of acidic pairs, e.g. Glu62-Glu63 in the major “closed-gate” polymorph. Linker residues 35–56 are cleaved or disordered (dashed line),<sup>29</sup> providing access to the Glu62-Glu63 site that probably binds  $Ca^{2+}$ .

to amyloid assemblies and stems from their shared structural features.

All known structures of patient-derived amyloid fibrils contain flattened protein molecules stacked in parallel in-register  $\beta$ -sheets connected by intermolecular hydrogen bonds, wherein identical residues spaced at 4.7–4.8 Å form periodic arrays (Fig. 2A and B).<sup>26</sup> In amorphous calcium phosphate (ACP), which is the precursor of the hydroxyapatite mineral in the bone and calcific deposits, the shortest Ca–Ca spacing is also 4.7 Å. This stereochemical complementarity between amyloid and ACP suggests that arrays of acidic residues (Glu or Asp) on the amyloid surface can bind ACP and  $Ca^{2+}$ , facilitating both hydroxyapatite formation<sup>27</sup> and  $Ca^{2+}$ -mediated bone tracer uptake. If so, why do type-A ATTR fibrils preferentially uptake bone tracers?


The answers are suggested by the atomic structures of patient-derived type-A ATTR fibrils, a number of which have been determined by cryo-EM since 2019.<sup>28–31</sup> All ATTRwt and ATTRv fibrils, including Val20Ile, Gly47Glu, Val30Met, Ile84Ser, and Val122Ile, adopt a similar amyloid fold.<sup>31</sup> This similarity reflects common primary structures that typically differ by just one amino acid substitution in ATTRv vs. ATTRwt. N-terminal (Pro11-Lys35) and C-terminal (Gly57-Thr123) residue fragments comprise fibril cores; variable “gate” segment (Gly57-Gly67) generates structural polymorph-

ism (Fig. 3B). All patients feature a “closed-gate” polymorph (Fig. 2B and 3A) containing exposed Glu62-Glu63 pair from the sole acidic-rich segment, Glu61-Glu62-Glu63-Phe64-Val65-Glu66. This pair forms a periodic ionic array along the fibril side; similarly, parenchymal type-I and type-II fibrils of Alzheimer’s  $A\beta_{1-42}$  peptide feature Glu22-Asp23 arrays that bind metal ions observed by cryoEM (Fig. 2A). We postulate that in ATTR type-A fibrils, exposed acidic pairs from Glu61-Glu66 segment bind  $Ca^{2+}$  ions that form surface arrays and mediate both calcification and bone tracer uptake. Conformational variability, structural disordering and/or partial truncation of the “gate” segment reported in some patient-specific polymorphs (Fig. 3B) potentially contribute to variable patient-specific tracer uptake observed by <sup>99m</sup>Tc scintigraphy.

This hypothetical mechanism is consistent with lack of tracer uptake by ATTR type-B fibrils, whose atomic structures are currently unknown. We speculate that in full-length transthyretin comprising type-B fibrils, residues 35–56 linking the “gate” to the N-terminal segment may obstruct Glu62-Glu63 and/or change the amyloid conformation to block the radiotracer binding. Patient-derived type-B fibrils structures, which are currently under investigation, will test this idea.

Unlike ATTR, antibody light chain variable domains that comprise AL deposits have highly variable amino acid





**Fig. 3** Cryo-EM structures of cardiac patient-derived ATTR and AL fibrils suggest calcium-mediated radiotracer binding sites. ATTR type-A fibrils have similar folds with alternative “gate” conformations leading to fibril polymorphism. (A) The major “closed-gate” polymorph. (B) Alternative polymorphs. All patients featured the “closed-gate” polymorph; some had additional polymorphs.<sup>31</sup> Acidic-rich segment Glu61-Glu62-Glu63-Phe64-Val65-Glu66 (red). (C) Cardiac AL fibrils are highly polymorphic. Only one structure features an exposed acidic-rich segment, Glu80-Asp81-Glu82-Ala83-Glu84-Asp84 (red).

sequences, with each AL patient featuring a unique primary structure of the fibril-forming protein. This translates into structural variability of AL amyloid folds, several of which have been determined since 2019 (Fig. 3C).<sup>32–34</sup> Of the four available structures of cardiac AL fibrils, only one features exposed acidic pairs from the sole acidic-rich segment, Glu80-Asp81-Glu82-Ala83-Glu84-Asp84. We propose that: (i)  $\text{Ca}^{2+}$  and radiotracer binding by such exposed acidic pairs potentially produces false positives in ATTR scintigraphy; (ii) variable (typically diminished) exposure of the acidic-rich segment Glu80-Asp84 in AL fibrils probably contributes to variable (generally

diminished) tracer uptake and microcalcification detected in AL vs. ATTR patients.<sup>10,16,17</sup>

The sole currently available AL patient-derived fibril structure that features an exposed acidic-rich segment belongs to  $\lambda 6$  subfamily of the  $\lambda$  isotype, which is responsible for approximately 1/4 and 3/4 of all AL cases, respectively.<sup>7</sup> Amino acid sequence in this segment is highly conserved in the  $\lambda$  isotype, but in  $\kappa$  isotype (which accounts for nearly 1/4 of AL cases) this sequence is less acidic and less conserved.<sup>35</sup> Due to high sequence and structural variability of the light chain variable domains, which form the fibril core in AL deposits, more



structural studies of patient-derived AL fibrils are needed to definitively link exposed acidic-rich segments with false positives in the ATTR diagnostics using  $^{99m}\text{Tc}$  scintigraphy.

## 6. Summary, open question and future directions

In conclusion, atomic structures of patient-derived cardiac amyloids support the notion that fibril-specific uptake of  $^{99m}\text{Tc}$ -labeled bone tracers involves calcium-mediated pyrophosphate or diphosphonate binding to amyloids, as well as to amyloid-associated calcific deposits. We postulate that stereochemical complementarity between the organic (acidic residue pairs on amyloid surface) and inorganic phases ( $\text{Ca}^{2+}/\text{ACP}$  and  $^{99m}\text{Tc}$ -PYP/DPD/HMDP) promotes both calcification and bone tracer uptake by type-A ATTR fibrils and by a subset of AL fibrils featuring acidic residue pairs on their surface (Fig. 3). This new concept helps explain why both calcification and tracer uptake are generally increased in ATTR *vs.* AL patients with cardiac amyloidosis.

Several questions remain open. First, relative amounts of PYP/DPD/HMDP tracers that bind to amyloid *vs.* amyloid-associated calcific deposits *in vivo* remain to be determined. Second, it remains unclear why  $^{99m}\text{Tc}$ -labeled methyl diphosphonate bone tracer (MDP) shows low sensitivity for cardiac amyloidosis. Greater rotational flexibility of PYP and DPD/HMDP might be a factor contributing to their increased binding to amyloid as compared to MDP. Third, the proposed concept applies to bone tracers that chelate to  $\text{Ca}^{2+}$ , such as PYP and diphosphonates; the other type of currently used  $^{18}\text{F}$ -labeled positron emission tomography bone tracer NaF binds through a different mechanism.<sup>36</sup> Fourth, tracer uptake *in vivo* is probably influenced by other factors, including calcium-binding extracellular matrix components such as collagens<sup>14,27</sup> and heparan sulfate, a ubiquitous amyloid cofactor.<sup>3</sup> These and other auxiliary molecules are found in amyloid deposits and, we propose, can directly bind to amyloids and influence their formation, structure, interactions with other ligands, and biological properties. Future studies of amyloid complexes with these factors,  $\text{Ca}^{2+}$ , and radiotracers will test these concepts, and will also explore potential binding of  $\text{Ca}^{2+}$  and radiotracers to pre-fibrillar amyloid oligomers. Finally, cryo-EM studies of other patient-derived amyloids, including type-B ATTR fibrils and additional AL fibril polymorphs, will shed more light on the structural and ligand binding properties of these remarkable protein polymers.

## Author contributions

EL – Visualization, methodology, writing – review and editing. SJ – Investigation, writing – review and editing, funding acquisition. OG – Conceptualization, methodology, writing – original draft, review and editing, funding acquisition.

## Ethical approval

This research does not involve any human or animal studies (exemption 4 by the Institutional Review Board). The research was conducted in full compliance with institutional ethics rules (IRB approval protocol # 20-2249).

## Abbreviations

A $\beta$	Alzheimer's amyloid-beta peptide
ACP	Amorphous calcium phosphate
AApoAI	Amyloid apolipoprotein A-I
AL	Amyloid light chain
ATTR	Amyloid transthyretin
Cryo-EM	Electron cryo-microscopy
DPD	3,3-Diphosphono-1,2-propanodicarboxylate
HMDP	Hydroxymethylene diphosphonate
PYP	Pyrophosphate

## Data availability

All original data for the minireview “**Molecular basis for non-invasive diagnostics of cardiac amyloids using bone tracers**” has been previously published. Atomic structures of amyloids are available in the protein data bank (pdb); access numbers (PDB ID) are included in the manuscript. The published paper will be available *via* PubMed and upon request from authors.

## Conflicts of interest

None of the authors has any conflicts of interests to declare.

## Acknowledgements

This research was supported by NIH grants R01 GM067260 and R01 GM135158. We thank Drs Navneet Narula and Jagat Narula who stimulated our interest in cardiac amyloid calcification.

## References

- 1 J. N. Buxbaum, A. Dispenzieri, D. S. Eisenberg, M. Fändrich, G. Merlini, M. J. M. Saraiva, Y. Sekijima and P. Westermark, Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee, *Amyloid*, 2022, **29**, 213–219.
- 2 N. Leung and S. H. Nasr, Update on classification, etiology, and typing of renal Amyloidosis: A review, *Am. J. Kidney Dis.*, 2024, DOI: [10.1053/j.ajkd.2024.01.530](https://doi.org/10.1053/j.ajkd.2024.01.530).



- 3 E. Lewkowicz, S. Jayaraman and O. Gursky, Protein amyloid cofactors: Charged side-chain arrays meet their match?, *Trends Biochem. Sci.*, 2021, **46**, 626–629.
- 4 J. M. Griffin, H. Rosenblum and M. S. Maurer, Pathophysiology and therapeutic approaches to cardiac amyloidosis, *Circ. Res.*, 2021, **128**, 1554–1575.
- 5 R. Saro, D. Pavan, A. Porcari, G. Sinagra and M. Mojoli, Lights and shadows of clinical applications of cardiac scintigraphy with bone tracers in suspected amyloidosis, *J. Clin. Med.*, 2023, **12**, 7605.
- 6 A. Porcari, G. Sinagra, J. D. Gillmore, M. Fontana and P. N. Hawkins, Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy, *Eur. J. Intern. Med.*, 2024, **123**, 29–36.
- 7 V. Santhorawala, Systemic light chain amyloidosis, *N. Engl. J. Med.*, 2024, **390**, 2295–2307.
- 8 K. Konstantoulea, N. Louros, F. Rousseau and J. Schymkowitz, Heterotypic interactions in amyloid function and disease, *FEBS J.*, 2022, **289**, 2025–2046.
- 9 U. Thelander, Presented in part at the XIX International Symposium on Amyloidosis, Rochester MN, USA, May 2024.
- 10 J. D. Gillmore, M. S. Maurer, R. H. Falk, G. Merlini, T. Damy, A. Dispenzieri, A. D. Wechalekar, J. L. Berk, C. C. Quarta, M. Grogan, H. J. Lachmann, S. Bokhari, A. Castano, S. Dorbala, G. B. Johnson, A. W. J. M. Glaudemans, T. Rezk, M. Fontana, G. Palladini, P. Milani, P. L. Guidalotti, K. Flatman, T. Lane, F. W. Vonberg, C. J. Whelan, J. C. Moon, F. L. Ruberg, E. J. Miller, D. F. Hutt, B. P. Hazenberg, C. Rapezzi and P. N. Hawkins, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, *Circulation*, 2016, **133**, 2404–2412.
- 11 S. Dorbala, S. Cuddy and R. H. Falk, How to image cardiac amyloidosis, *JACC Cardiovasc. Imaging*, 2020, **13**, 1368–1383.
- 12 R. Rettl, R. Calabretta, F. Duca, C. Binder, C. Kronberger, R. Willixhofer, M. Poledniczek, C. Donà, C. Nitsche, D. Beitzke, C. Loewe, M. Auer-Grumbach, D. Bonderman, S. Kastl, C. Hengstenberg, R. Badr Eslam, J. Kastner, J. Bergler-Klein, M. Hacker and A. Kammerlander, Reduction in <sup>99m</sup>Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy, *Amyloid*, 2024, **31**, 42–51.
- 13 J. W. Jackson, J. S. Foster, E. B. Martin, S. Macy, C. Wooliver, M. Balachandran, T. Richey, R. E. Heidel, A. D. Williams, S. J. Kennel and J. S. Wall, Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal, *Amyloid*, 2023, **30**, 249–260.
- 14 S. Ricagno, T. Schulte, A. Chaves-Sanjuan, V. Speranzini, K. Sicking, G. Mazzini, P. Rognoni, S. Caminito, P. Milani, C. Marabelli, A. Corbelli, L. Diomede, F. Fiordaliso, L. Anastasia, C. Pappone, G. Merlini, M. Bolognesi, M. Nuvolone, R. Fernandez-Busnadiego and G. Palladini, Helical superstructures between amyloid and collagen VI in heart-derived fibrils from a patient with Light Chain Amyloidosis, *Res. Sq.*, 2023, DOI: [10.21203/rs.3.rs-3625869/v1](https://doi.org/10.21203/rs.3.rs-3625869/v1), preprint.
- 15 C. L. Hoop, J. Zhu, S. Bhattacharya, C. A. Tobita, S. E. Radford and J. Baum, Collagen I weakly interacts with the  $\beta$ -sheets of  $\beta$ 2-microglobulin and enhances conformational exchange to induce amyloid formation, *J. Am. Chem. Soc.*, 2020, **142**, 1321–1331.
- 16 U. Thelander, G. T. Westermark, G. Antoni, S. Estrada, A. Zancanaro, E. Ihse and P. Westermark, Cardiac microcalcifications in transthyretin (ATTR) amyloidosis, *Int. J. Cardiol.*, 2022, **352**, 84–91.
- 17 A. Mori, Y. Saito, K. Nakamura, T. Iida, S. Akagi, M. Yoshida, M. Taniyama, T. Miyoshi and H. Ito, Microcalcification and <sup>99m</sup>Tc-Pyrophosphate uptake without increased bone metabolism in cardiac tissue from patients with transthyretin cardiac amyloidosis, *Int. J. Mol. Sci.*, 2023, **24**, 1921.
- 18 G. P. Keeling, F. Baark, O. L. Katsamenis, J. Xue, P. J. Blower, S. Bertazzo and R. T. M. de Rosales, <sup>68</sup>Ga-bisphosphonates for the imaging of extraosseous calcification by positron emission tomography, *Sci. Rep.*, 2023, **13**, 14611.
- 19 L. R. Martín, L. R. Santiago, I. V. Korendovych, M. Sodupe and J.-D. Maréchal, in *Methods in Enzymology*, ed. I. V. Korendovych, Academic Press, 2024, vol. 697, pp. 211–245.
- 20 Y. Yang, D. Arseni, W. Zhang, M. Huang, S. Lövestam, M. Schweighauser, A. Kotecha, A. G. Murzin, S. Y. Peak-Chew, J. Macdonald, I. Lavenir, H. J. Garringer, E. Gelpi, K. L. Newell, G. G. Kovacs, R. Vidal, B. Ghetti, B. Ryskeldi-Falcon, S. H. W. Scheres and M. Goedert, Cryo-EM structures of amyloid- $\beta$  42 filaments from human brains, *Science*, 2022, **375**, 167–172.
- 21 J. George, M. Rappaport, S. Shimoni, S. Goland, I. Voldarsky, Y. Fabricant, O. Edri, V. Cuciuc, S. Lifshitz, S. Tshori and M. Fassler, A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model, *Eur. Heart J.*, 2020, **41**, 1260–1270.
- 22 F. E. Buroni, M. G. Persico, L. Lodola, M. Concardi and C. Aprile, In vitro study: binding of <sup>99m</sup>Tc-DPD to synthetic amyloid fibrils, *Curr. Issues Pharm. Med. Sci.*, 2015, **28**, 231–235.
- 23 C. Cantarutti, M. C. Mimmi, G. Verona, W. Mandaliti, G. W. Taylor, P. P. Mangione, S. Giorgetti, V. Bellotti and A. Corazza, Calcium binds to transthyretin with low affinity, *Biomolecules*, 2022, **12**, 1066.
- 24 M. A. Stats and J. R. Stone, Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis, *Cardiovasc. Pathol.*, 2016, **25**, 413–417.
- 25 X. Wang, M. Kirberger, F. Qiu, G. Chen and J. J. Yang, Towards predicting Ca<sup>2+</sup>-binding sites with different coordination numbers in proteins with atomic resolution, *Proteins*, 2009, **75**, 787–798.
- 26 P. C. Ke, R. Zhou, L. C. Serpell, R. Riek, T. P. J. Knowles, H. A. Lashuel, E. Gazit, I. W. Hamley, T. P. Davis,



- M. Fändrich, D. E. Otzen, M. R. Chapman, C. M. Dobson, D. S. Eisenberg and R. Mezzenga, Half a century of amyloids: Past, present and future, *Chem. Soc. Rev.*, 2020, **49**, 5473–5509.
- 27 S. Jayaraman, N. Narula, J. Narula and O. Gursky, Amyloid and collagen templates in aortic valve calcification, *Trends Mol. Med.*, 2024, S1471-4914(24)00115-1.
- 28 M. Schmidt, S. Wiese, V. Adak, J. Engler, S. Agarwal, G. Fritz, P. Westermark, M. Zacharias and M. Fändrich, Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis, *Nat. Commun.*, 2019, **10**, 5008.
- 29 M. Steinebrei, J. Gottwald, J. Baur, C. Röcken, U. Hegenbart, S. Schönland and M. Schmidt, Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis, *Nat. Commun.*, 2022, **13**, 6398.
- 30 I. Iakovleva, M. Hall, M. Oelker, L. Sandblad, I. Anan and A. E. Sauer-Eriksson, Structural basis for transthyretin amyloid formation in vitreous body of the eye, *Nat. Commun.*, 2021, **12**, 7141.
- 31 B. A. Nguyen, V. Singh, S. Afrin, A. Yakubovska, L. Wang, Y. Ahmed, R. Pedretti, M. d. C. Fernandez-Ramirez, P. Singh, M. Pękała, L. O. Cabrera Hernandez, S. Kumar, A. Lemoff, R. Gonzalez-Prieto, M. R. Sawaya, D. S. Eisenberg, M. D. Benson and L. Saelices, Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy, *Nat. Commun.*, 2024, **15**, 581.
- 32 P. Swuec, F. Lavatelli, M. Tasaki, C. Pissoni, P. Rognoni, M. Maritan, F. Brambilla, P. Milani, P. Mauri, C. Camilloni, G. Palladini, G. Merlini, S. Ricagno and M. Bolognesi, Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient, *Nat. Commun.*, 2019, **10**, 1269.
- 33 L. Rademaker, Y.-H. Lin, K. Annamalai, S. Huhn, U. Hegenbart, S. O. Schönland, G. Fritz, M. Schmidt and M. Fändrich, Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis, *Nat. Commun.*, 2019, **10**, 1103.
- 34 L. Rademaker, S. Karimi-Farsijani, G. Andreotti, J. Baur, M. Neumann, S. Schreiner, N. Berghaus, R. Motika, C. Haupt, P. Walther, V. Schmidt, S. Huhn, U. Hegenbart, S. O. Schönland, S. Wiese, C. Read, M. Schmidt and M. Fändrich, Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM, *Nat. Commun.*, 2021, **12**, 6434.
- 35 R. van der Kant, N. Louros, J. Schymkowitz and F. Rousseau, Thermodynamic analysis of amyloid fibril structures reveals a common framework for stability in amyloid polymorphs, *Structure*, 2022, **30**, 1178–1189.
- 36 L. X. Zhang, P. Martineau, V. Finnerty, G. Giraldeau, M.-C. Parent, F. Harel and M. Pelletier-Galarneau, Comparison of <sup>18</sup>F-sodium fluoride positron emission tomography imaging and <sup>99m</sup>Tc-pyrophosphate in cardiac amyloidosis, *J. Nucl. Cardiol.*, 2022, **29**, 1132–1140.

